Skip to main content

Table 2 Body weight, heart weight, heart-to-body weight ratio, heart weight-to-tibia length ratio and left-ventricular wall thickness assessed by echocardiography

From: Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway

  ZL
(n = 7–10)
ZDF
(n = 7–8)
ZDF + Zn(ASA)2
(n = 5–6)
ZL + Zn(ASA)2
(n = 8–10)
Weights
 Body weight (g) 419 ± 9 376 ± 18 394 ± 27 416 ± 6
 Heart weight (g) 1.36 ± 0.03 1.22 ± 0.04 1.35 ± 0.14 1.32 ± 0.03
 Heart-to-body weight (g/kg) 3.26 ± 0.05 3.26 ± 0.11 3.39 ± 0.10 3.19 ± 0.07
 Heart weight-to-tibia length (g/cm) 0.32± 0.01 0.30 ± 0.01 0.33 ± 0.03 0.30 ± 0.01
Left-ventricular wall thickness
 LVPW, d (mm) 2.49 ± 0.31 2.95 ± 0.42 1.95 ± 0.17 1.94 ± 0.20
 LVPW, s (mm) 3.20 ± 0.27 4.24 ± 0.40 3.16 ± 0.19 2.69 ± 0.25
  1. Values are mean ± SEM. ZL indicates Zucker lean, ZDF Zucker diabetic fatty acid, Zn(ASA) 2 zinc complex of acetylsalicylic acid, LVPW, d, thickness of the left ventricular posterior wall in diastole, LVPW, s thickness of the left ventricular posterior wall in systole, n number of animals analysed